311 related articles for article (PubMed ID: 20008242)
1. Novel therapies for relapsed myeloma.
Stewart AK
Hematology Am Soc Hematol Educ Program; 2009; ():578-86. PubMed ID: 20008242
[TBL] [Abstract][Full Text] [Related]
2. [New drugs in the treatment of multiple myeloma].
Oriol A; Motlló C
Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
4. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide in the treatment of relapsed multiple myeloma.
Forsberg PA; Mark TM
Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
[TBL] [Abstract][Full Text] [Related]
6. Current status of bortezomib in the treatment of multiple myeloma.
Cavo M
Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361
[TBL] [Abstract][Full Text] [Related]
7. Drugs: More shots on target.
Appel A
Nature; 2011 Dec; 480(7377):S40-2. PubMed ID: 22169800
[No Abstract] [Full Text] [Related]
8. Investigational treatments for multiple myeloma.
Bringhen S; Avonto I; Magarotto V; Boccadoro M; Palumbo A
Expert Opin Investig Drugs; 2006 Dec; 15(12):1565-82. PubMed ID: 17107282
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
10. Management of double-refractory multiple myeloma.
Meadows JP; Mark TM
Curr Hematol Malig Rep; 2013 Dec; 8(4):253-60. PubMed ID: 23975677
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and the current trends in multiple myeloma therapy.
Dmoszyńska A
Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
[TBL] [Abstract][Full Text] [Related]
12. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
13. Clinical update: novel targets in multiple myeloma.
Anderson KC
Semin Oncol; 2004 Dec; 31(6 Suppl 16):27-32; discussion 33. PubMed ID: 15799242
[TBL] [Abstract][Full Text] [Related]
14. Novel agents in development for peripheral T-cell lymphoma.
O'Connor OA
Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
16. Future agents and treatment directions in multiple myeloma.
Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
[TBL] [Abstract][Full Text] [Related]
17. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
18. Future directions in immunomodulatory therapy.
Lonial S
Med Oncol; 2010 Jun; 27 Suppl 1():S62-6. PubMed ID: 20012563
[TBL] [Abstract][Full Text] [Related]
19. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]